(CLX) The Clorox - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1890541097
Stock: Cleaning, Personal Care, Food, Pet Supplies
Total Rating 42
Risk 64
Buy Signal -0.27
| Risk 5d forecast | |
|---|---|
| Volatility | 23.6% |
| Relative Tail Risk | 0.13% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.95 |
| Alpha | -26.92 |
| Character TTM | |
|---|---|
| Beta | 0.181 |
| Beta Downside | -0.202 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.45% |
| CAGR/Max DD | -0.14 |
EPS (Earnings per Share)
Revenue
Description: CLX The Clorox March 04, 2026
The Clorox Company (CLX) is a diversified consumer goods manufacturer and marketer. The companys business model relies on a broad portfolio of established brands across multiple categories.
CLX operates through four segments: Health and Wellness, Household, Lifestyle, and International. This structure allows for targeted management of distinct product lines and geographic markets. The consumer staples sector, in which Clorox operates, is generally characterized by stable demand and brand loyalty.
The Health and Wellness segment includes cleaning and disinfecting products, a category that has seen increased focus on hygiene in recent years. The Household segment features pet care and food storage items. The Lifestyle segment offers food products, water filtration, and natural personal care items, reflecting trends in health and wellness. The International segment mirrors these offerings globally, adapting to diverse consumer preferences.
Clorox distributes its products through a wide range of retail channels, including mass merchandisers, grocery stores, and e-commerce platforms. This multi-channel approach is typical for large consumer product companies seeking to maximize market penetration. For a deeper dive into specific financial metrics and competitive analysis, ValueRay can provide further insights.
Headlines to watch out for
- Commodity price fluctuations impact manufacturing costs
- Consumer demand for cleaning products drives revenue
- Retailer negotiations affect product placement and margins
- International currency exchange rates influence global sales
- Regulatory changes in product safety pose compliance risks
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 755.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 1.40 > 1.0 |
| NWC/Revenue: -9.16% < 20% (prev -1.37%; Δ -7.79% < -1%) |
| CFO/TA 0.18 > 3% & CFO 984.0m > Net Income 755.0m |
| Net Debt (2.99b) to EBITDA (1.31b): 2.27 < 3 |
| Current Ratio: 0.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.9m) vs 12m ago -2.20% < -2% |
| Gross Margin: 44.04% > 18% (prev 0.44%; Δ 4359 % > 0.5%) |
| Asset Turnover: 120.8% > 50% (prev 128.5%; Δ -7.69% > 0%) |
| Interest Coverage Ratio: 10.30 > 6 (EBITDA TTM 1.31b / Interest Expense TTM 106.0m) |
Altman Z'' 0.73
| A: -0.11 (Total Current Assets 1.73b - Total Current Liabilities 2.35b) / Total Assets 5.61b |
| B: 0.03 (Retained Earnings 190.0m / Total Assets 5.61b) |
| C: 0.20 (EBIT TTM 1.09b / Avg Total Assets 5.59b) |
| D: 0.03 (Book Value of Equity 162.0m / Total Liabilities 5.58b) |
| Altman-Z'' Score: 0.73 = B |
Beneish M -2.97
| DSRI: 1.18 (Receivables 671.0m/603.0m, Revenue 6.76b/7.17b) |
| GMI: 1.01 (GM 44.04% / 44.42%) |
| AQI: 0.96 (AQ_t 0.40 / AQ_t-1 0.42) |
| SGI: 0.94 (Revenue 6.76b / 7.17b) |
| TATA: -0.04 (NI 755.0m - CFO 984.0m) / TA 5.61b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of CLX shares?
As of March 11, 2026, the stock is trading at USD 115.87 with a total of 1,778,250 shares traded.
Over the past week, the price has changed by -4.36%, over one month by -4.59%, over three months by +14.27% and over the past year by -18.53%.
Over the past week, the price has changed by -4.36%, over one month by -4.59%, over three months by +14.27% and over the past year by -18.53%.
Is CLX a buy, sell or hold?
The Clorox has received a consensus analysts rating of 3.05.
Therefor, it is recommend to hold CLX.
- StrongBuy: 2
- Buy: 2
- Hold: 13
- Sell: 3
- StrongSell: 1
What are the forecasts/targets for the CLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 123.5 | 6.6% |
| Analysts Target Price | 123.5 | 6.6% |
CLX Fundamental Data Overview March 10, 2026
P/E Trailing = 18.766
P/E Forward = 16.2602
P/S = 2.0696
P/B = 41.403
P/EG = 2.3244
Revenue TTM = 6.76b USD
EBIT TTM = 1.09b USD
EBITDA TTM = 1.31b USD
Long Term Debt = 2.49b USD (from longTermDebt, last quarter)
Short Term Debt = 390.0m USD (from shortTermDebt, last quarter)
Debt = 3.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.99b USD (from netDebt column, last quarter)
Enterprise Value = 16.98b USD (13.99b + Debt 3.22b - CCE 227.0m)
Interest Coverage Ratio = 10.30 (Ebit TTM 1.09b / Interest Expense TTM 106.0m)
EV/FCF = 21.82x (Enterprise Value 16.98b / FCF TTM 778.0m)
FCF Yield = 4.58% (FCF TTM 778.0m / Enterprise Value 16.98b)
FCF Margin = 11.51% (FCF TTM 778.0m / Revenue TTM 6.76b)
Net Margin = 11.17% (Net Income TTM 755.0m / Revenue TTM 6.76b)
Gross Margin = 44.04% ((Revenue TTM 6.76b - Cost of Revenue TTM 3.78b) / Revenue TTM)
Gross Margin QoQ = 43.16% (prev 41.57%)
Tobins Q-Ratio = 3.02 (Enterprise Value 16.98b / Total Assets 5.61b)
Interest Expense / Debt = 0.87% (Interest Expense 28.0m / Debt 3.22b)
Taxrate = 25.12% (54.0m / 215.0m)
NOPAT = 817.7m (EBIT 1.09b * (1 - 25.12%))
Current Ratio = 0.74 (Total Current Assets 1.73b / Total Current Liabilities 2.35b)
Debt / Equity = -25.74 (negative equity) (Debt 3.22b / totalStockholderEquity, last quarter -125.0m)
Debt / EBITDA = 2.27 (Net Debt 2.99b / EBITDA 1.31b)
Debt / FCF = 3.84 (Net Debt 2.99b / FCF TTM 778.0m)
Total Stockholder Equity = 50.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.49% (Net Income 755.0m / Total Assets 5.61b)
RoE = 1502 % (out of range, set to none) (Net Income TTM 755.0m / Total Stockholder Equity 50.2m)
RoCE = 43.06% (EBIT 1.09b / Capital Employed (Equity 50.2m + L.T.Debt 2.49b))
RoIC = 30.51% (NOPAT 817.7m / Invested Capital 2.68b)
WACC = 5.47% (E(13.99b)/V(17.20b) * Re(6.58%) + D(3.22b)/V(17.20b) * Rd(0.87%) * (1-Tc(0.25)))
Discount Rate = 6.58% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.09%
[DCF] Terminal Value 86.88% ; FCFF base≈744.8m ; Y1≈788.4m ; Y5≈935.4m
[DCF] Fair Price = 204.6 (EV 27.73b - Net Debt 2.99b = Equity 24.74b / Shares 120.9m; r=5.90% [WACC]; 5y FCF grow 6.46% → 2.90% )
EPS Correlation: 32.79 | EPS CAGR: 1.59% | SUE: -0.11 | # QB: 0
Revenue Correlation: -24.05 | Revenue CAGR: -2.06% | SUE: 0.41 | # QB: 0
EPS current Year (2026-06-30): EPS=5.92 | Chg7d=+0.000 | Chg30d=-0.024 | Revisions Net=-3 | Growth EPS=-23.3% | Growth Revenue=-8.5%
EPS next Year (2027-06-30): EPS=6.82 | Chg7d=+0.000 | Chg30d=+0.074 | Revisions Net=+7 | Growth EPS=+15.1% | Growth Revenue=+5.1%
[Analyst] Revisions Ratio: -0.20 (6 Up / 9 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 2.6% (Discount Rate 7.9% - Earnings Yield 5.3%)
[Growth] Growth Spread = +2.5% (Analyst 5.1% - Implied 2.6%)
P/E Forward = 16.2602
P/S = 2.0696
P/B = 41.403
P/EG = 2.3244
Revenue TTM = 6.76b USD
EBIT TTM = 1.09b USD
EBITDA TTM = 1.31b USD
Long Term Debt = 2.49b USD (from longTermDebt, last quarter)
Short Term Debt = 390.0m USD (from shortTermDebt, last quarter)
Debt = 3.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.99b USD (from netDebt column, last quarter)
Enterprise Value = 16.98b USD (13.99b + Debt 3.22b - CCE 227.0m)
Interest Coverage Ratio = 10.30 (Ebit TTM 1.09b / Interest Expense TTM 106.0m)
EV/FCF = 21.82x (Enterprise Value 16.98b / FCF TTM 778.0m)
FCF Yield = 4.58% (FCF TTM 778.0m / Enterprise Value 16.98b)
FCF Margin = 11.51% (FCF TTM 778.0m / Revenue TTM 6.76b)
Net Margin = 11.17% (Net Income TTM 755.0m / Revenue TTM 6.76b)
Gross Margin = 44.04% ((Revenue TTM 6.76b - Cost of Revenue TTM 3.78b) / Revenue TTM)
Gross Margin QoQ = 43.16% (prev 41.57%)
Tobins Q-Ratio = 3.02 (Enterprise Value 16.98b / Total Assets 5.61b)
Interest Expense / Debt = 0.87% (Interest Expense 28.0m / Debt 3.22b)
Taxrate = 25.12% (54.0m / 215.0m)
NOPAT = 817.7m (EBIT 1.09b * (1 - 25.12%))
Current Ratio = 0.74 (Total Current Assets 1.73b / Total Current Liabilities 2.35b)
Debt / Equity = -25.74 (negative equity) (Debt 3.22b / totalStockholderEquity, last quarter -125.0m)
Debt / EBITDA = 2.27 (Net Debt 2.99b / EBITDA 1.31b)
Debt / FCF = 3.84 (Net Debt 2.99b / FCF TTM 778.0m)
Total Stockholder Equity = 50.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.49% (Net Income 755.0m / Total Assets 5.61b)
RoE = 1502 % (out of range, set to none) (Net Income TTM 755.0m / Total Stockholder Equity 50.2m)
RoCE = 43.06% (EBIT 1.09b / Capital Employed (Equity 50.2m + L.T.Debt 2.49b))
RoIC = 30.51% (NOPAT 817.7m / Invested Capital 2.68b)
WACC = 5.47% (E(13.99b)/V(17.20b) * Re(6.58%) + D(3.22b)/V(17.20b) * Rd(0.87%) * (1-Tc(0.25)))
Discount Rate = 6.58% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.09%
[DCF] Terminal Value 86.88% ; FCFF base≈744.8m ; Y1≈788.4m ; Y5≈935.4m
[DCF] Fair Price = 204.6 (EV 27.73b - Net Debt 2.99b = Equity 24.74b / Shares 120.9m; r=5.90% [WACC]; 5y FCF grow 6.46% → 2.90% )
EPS Correlation: 32.79 | EPS CAGR: 1.59% | SUE: -0.11 | # QB: 0
Revenue Correlation: -24.05 | Revenue CAGR: -2.06% | SUE: 0.41 | # QB: 0
EPS current Year (2026-06-30): EPS=5.92 | Chg7d=+0.000 | Chg30d=-0.024 | Revisions Net=-3 | Growth EPS=-23.3% | Growth Revenue=-8.5%
EPS next Year (2027-06-30): EPS=6.82 | Chg7d=+0.000 | Chg30d=+0.074 | Revisions Net=+7 | Growth EPS=+15.1% | Growth Revenue=+5.1%
[Analyst] Revisions Ratio: -0.20 (6 Up / 9 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 2.6% (Discount Rate 7.9% - Earnings Yield 5.3%)
[Growth] Growth Spread = +2.5% (Analyst 5.1% - Implied 2.6%)